All In Biotech

Drug Trial Radar · NCT00495508

Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007)

Last checked: Nov 20, 2026Latest source record: Jun 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Oct 2006

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
EpicentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medecins Sans Frontieres, Netherlands; University of Cape Town; Shoklo Malaria Research Unit
First posted
Jul 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A) for the treatment of uncomplicated malaria during second and third trimester pregnancy to oral Quinine hydrochloride. The PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is considered as the primary efficacy criterion. Newborns will be followed for growth and development indicators.

Conditions

  • Malaria

Interventions

  • QuinineDrug

  • artemether / lumefantrineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42 or at delivery.Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Epicentre

    Mbarara, Mbarara District, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.